company background image
ISAB

Inhalation Sciences Sweden NGM:ISAB Stock Report

Last Price

kr6.34

Market Cap

kr72.1m

7D

-4.2%

1Y

-39.6%

Updated

13 Aug, 2022

Data

Company Financials +
ISAB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ISAB Stock Overview

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research.

Inhalation Sciences Sweden Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inhalation Sciences Sweden
Historical stock prices
Current Share Pricekr6.34
52 Week Highkr11.30
52 Week Lowkr5.30
Beta1.36
1 Month Change16.12%
3 Month Change-14.09%
1 Year Change-39.62%
3 Year Change-5.37%
5 Year Changen/a
Change since IPO-31.46%

Recent News & Updates

Shareholder Returns

ISABSE Life SciencesSE Market
7D-4.2%5.8%2.3%
1Y-39.6%-52.0%-21.8%

Return vs Industry: ISAB exceeded the Swedish Life Sciences industry which returned -52% over the past year.

Return vs Market: ISAB underperformed the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is ISAB's price volatile compared to industry and market?
ISAB volatility
ISAB Average Weekly Movement11.9%
Life Sciences Industry Average Movement7.8%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.7%
10% least volatile stocks in SE Market4.5%

Stable Share Price: ISAB is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ISAB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20049Manoush Masarrathttps://www.inhalation.se

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research. Its products include PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. The company was founded in 2004 and is based in Huddinge, Sweden.

Inhalation Sciences Sweden Fundamentals Summary

How do Inhalation Sciences Sweden's earnings and revenue compare to its market cap?
ISAB fundamental statistics
Market Capkr72.12m
Earnings (TTM)-kr16.56m
Revenue (TTM)kr8.64m

8.3x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISAB income statement (TTM)
Revenuekr8.64m
Cost of Revenuekr2.86m
Gross Profitkr5.79m
Other Expenseskr22.34m
Earnings-kr16.56m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.46
Gross Margin66.93%
Net Profit Margin-191.59%
Debt/Equity Ratio10.5%

How did ISAB perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ISAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISAB?

Other financial metrics that can be useful for relative valuation.

ISAB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.4x
Enterprise Value/EBITDA-4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ISAB's PS Ratio compare to its peers?

ISAB PS Ratio vs Peers
The above table shows the PS ratio for ISAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.5x
ATANA Attana
15.5x9.4%kr133.3m
ALPH AlphaHelix Molecular Diagnostics
1xn/akr46.7m
MAGLE Magle Chemoswed Holding
1.9xn/akr257.0m
CLINE B Cline Scientific
7.8xn/akr22.6m
ISAB Inhalation Sciences Sweden
8.3x47.5%kr72.1m

Price-To-Sales vs Peers: ISAB is expensive based on its Price-To-Sales Ratio (8.3x) compared to the peer average (6.5x).


Price to Earnings Ratio vs Industry

How does ISAB's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Sales vs Industry: ISAB is expensive based on its Price-To-Sales Ratio (8.3x) compared to the Swedish Life Sciences industry average (7.6x)


Price to Sales Ratio vs Fair Ratio

What is ISAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.3x
Fair PS Ratio12.8x

Price-To-Sales vs Fair Ratio: ISAB is good value based on its Price-To-Sales Ratio (8.3x) compared to the estimated Fair Price-To-Sales Ratio (12.8x).


Share Price vs Fair Value

What is the Fair Price of ISAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ISAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ISAB's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Inhalation Sciences Sweden forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


125.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ISAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ISAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ISAB's revenue (47.5% per year) is forecast to grow faster than the Swedish market (10.9% per year).

High Growth Revenue: ISAB's revenue (47.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ISAB's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Inhalation Sciences Sweden performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ISAB is currently unprofitable.

Growing Profit Margin: ISAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ISAB is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.

Accelerating Growth: Unable to compare ISAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISAB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (92.3%).


Return on Equity

High ROE: ISAB has a negative Return on Equity (-101.74%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Inhalation Sciences Sweden's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ISAB's short term assets (SEK18.0M) exceed its short term liabilities (SEK4.8M).

Long Term Liabilities: ISAB's short term assets (SEK18.0M) exceed its long term liabilities (SEK1.2M).


Debt to Equity History and Analysis

Debt Level: ISAB has more cash than its total debt.

Reducing Debt: ISAB's debt to equity ratio has reduced from 89.8% to 10.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISAB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ISAB has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 18% each year.


Discover healthy companies

Dividend

What is Inhalation Sciences Sweden current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISAB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ISAB has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Manoush Masarrat (45 yo)

2.92yrs

Tenure

Mr. Manoush Masarrat has been Chief Executive Officer at Inhalation Sciences Sweden AB (publ) since September 16 2019. Mr. Masarrat had served as Director of Inhalation Sciences Sweden AB (publ) since Dece...


Board Members

Experienced Board: ISAB's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Inhalation Sciences Sweden AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Inhalation Sciences Sweden AB (publ)
  • Ticker: ISAB
  • Exchange: NGM
  • Founded: 2004
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr72.122m
  • Shares outstanding: 11.38m
  • Website: https://www.inhalation.se

Number of Employees


Location

  • Inhalation Sciences Sweden AB (publ)
  • Novum floor 6
  • Elevator E
  • Huddinge
  • Stockholm County
  • 141 57
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.